Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02002091
Other study ID # UAlgiers FM 401/desm/07
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 2009
Est. completion date December 2014

Study information

Verified date June 2024
Source University of Algiers
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

- It is a prospective,observational, cohort study - The main purpose of the study is to assess the prevalence of diabetic chronic complications in newly diagnosed type 2 diabetics in suburban area of Algiers. - The secondary purpose is to study the impact of diabetic renal complications as a risk factor on the atherothrombotic events.


Description:

To reach the two purposes, we need to conduct a cohort study: - The cohort population is type 2 diabetes patients that have been recruited in a consecutive and exhaustive way. The first consultation is performed in hospital or in one of 12 primary care units of Ain-Taya's health sector in Est suburb of Algiers . When a glycemia is found at 1.26 g/litre or over, the patient is referred to principal investigator to confirm the diagnosis of type 2 diabetes ,to recruit him and proceed to complete screening for chronic complications - For the main purpose, we evaluate the prevalence of micro and macrovascular complications, at the time of diagnosis, in type2 diabetes patients that have been recruited. For some complications as Diabetic Kidney Disease, we have to follow up the patient at least three months to confirm the chronic nature of the nephropathy. - For the secondary purpose, the cohort population is followed up for one year, the patients are treated commonly. We'll check out all the cardiovascular events linked to atherothrombosis.Two groups of patients might be formed: - The first group is composed of all diabetic patients, with chronic Kidney disease (CKD) and without atherothrombotic disease. CKD is defined by albuminuria (micro or macroalbuminuria) and/or renal failure, present for more than 3 months . All the patients with CKD are considered to be "exposed" to atherothrombotic disease. - The second group is composed of all diabetic patients, without CKD and without atherothrombotic disease. This group is considered to be "not exposed" to the atherothrombotic disease. We will compare the two groups, on occurence of cardiovascular events, after adjustment of age and major cardiovascular risk factors, and after excluding patients 'not exposed' having had a prior treatment with conversion enzyme inhibitor or angiotensin receptor antagonist . - The size of the sample is calculated with statistical formula: n= E2 Po Qo / i2 n= size of the sample E= 1.96 with error risk : alpha= 5% Po= 30% Qo= 1-Po "n" is at least egal to 323 patients - Statistical analysis is performed with epi info 6.04b and all tests are performed with an error risk alpha= 5% - Descriptive statistics of patients characteristics: - For quantitative variables,we will calculate means,standard deviations, median and quantiles. - for qualitative variables, percentage will be calculated. - Comparative statistics according to existence of renal disease or not - Khi-square test is performed for qualitative variables - Student test: for two means comparison - Anova test: to compare more than two means - Multivariate analysis will be done on SPSS v: 21 software program, adjustment will be done for age, sexe and major cardiovascular risk factors.


Recruitment information / eligibility

Status Completed
Enrollment 327
Est. completion date December 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Men or women aged from 40 to 70 years - Newly diagnosed type 2 diabetes - Never treated for diabetes Exclusion Criteria: - Gestational diabetes

Study Design


Intervention

Other:
no specific treatment
lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.

Locations

Country Name City State
Algeria Internal Medicine department - Ain-Taya's Hospital Ain - Taya Algiers

Sponsors (7)

Lead Sponsor Collaborator
University of Algiers Bab El Oued Teaching Hospital, Birtraria Hospital, Hopital Ain Taya, Hôpital Mustapha Pacha, National Institute of public Health, Algeria, Parnet Hospital

Country where clinical trial is conducted

Algeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and Prevalence of Patients With Diabetic Retinopathy Conventional ophtalmoscopy has been used to screen for diabetic retinopathy by an ophtalmologist at his office.
Retinal angiography was performed if indicated by the ophtalmologist
At recruitment
Primary Number of Patients With Distal Diabetic Neuropathy All 327 patients had a neurological examination by the same physician to screen for Distal Diabetic Neuropathy:
Distal sensory testing: including 10 g monofilament test, vibration perception with 128 Hz tuning fork, temperature, touch , prickling and pain perception
Ankles and knees reflex testing
Muscle strength testing (quadriceps and tibialis anterior)
We use the Michigan Neuropathy Screening Instrument score. We consider the diagnosis of Distal Diabetic Neuropathy if the score is up of 2 in at least one food. The MNSI score is ranged from 0 to 5 for each food
Use of neuropathic pain score (DN4), if the DN4 is found up or egal to 4 we consider the diagnosis of neuropathic pain. The DN4 score is ranged from 0 to 10
At recruitment
Primary Number of Patients With Chronic Kidney Disease (CKD) We screened for albuminuria or microalbuminuria in 24h urine collection with turbidimetry or immuno turbidimetry method ( performed 3 times in 4 or 6 months )
Measurement of albumine- to- creatinine ratio (ACR), Albuminuria was diagnosed if ACR > or egal to 30 mg/g at least twice in 4 to 6 months. We ensure before performing ACR that there was no dysglycaemia, no urinary infection, no fever nor forced diuresis before we evaluate the urine sample.
Cyto bacteriological examination and urine culture
Serum creatinine repeated 2 to 3 time within 4 to 6 months
Glomerular filtration rate was assessed with the Modification of Diet in Renal disease study equation (MDRD)
Renal and urine tract echography to measure the kidneys and to screen for urine tract dilatation We made the diagnosis of Chronic Kidney Disease (CKD) if the glomerular filtration rate was < 60 ml/min/1.73 m² and/or ACR > or equal to 30 mg/g with a permanent character
At recruitment
Primary Number of Patients With Hypertension Blood pressure measurement by electronic tensiometer (OMRON 3 or 4) on the right and left arm, after 10 mn of supine position.
Three measures were performed with respect of one minute interval between each measure.
Mean blood pressure is calculated
Three other measures are performed in Three ulterior consultations
Hypertension is diagnosed if the mean blood pressure >= 140 /90 mm Hg
At recruitment
Primary Number of Patients With Silent Myocardial Ischemia 9 derivations resting electrocardiogram (ECG)
Echocardiography
Standard ECG stress test
Stress Myocardial Perfusion scintigraphy if patients are not able to perform ECG stress test
Coronary angiography if the exercise ECG stress test or stress myocardial perfusion scintigraphy suggest high probability of coronary heart disease
At recruitment
Primary Number of Patients With Lower Extremity Artery Disease Search for history of intermittent claudication
Complete vascular examination with Ankle-Brachial Index (ABI) measurement.
Lower limb duplex ultrasonography.
At recruitment
Primary Number of Patients With Carotid Artery Stenosis Screening for carotid murmur at clinical examination by the same physician for all patients
Carotid duplex ultrasonography with intima-media thickness measurement. All atherosclerotic lesions were reported.
At recruitment
Primary Number of Patients With Renal Artery Stenosis or Elevated Intrarenal Resistance Index - Renal artery duplex ultrasonography has been performed only if the patient presents a resistant hypertension treated with four drugs, including a diuretic or if blood pressure was over 180/10 mm Hg at recruitement. At recruitment
Primary Number of Patients With Cardiac Autonomic Neuropathy Conditions of the Ewing tests: fasting, resting at least 30mn, no hypoglycemia and no effort within 24hours, no drugs that interfere with heart rate.
Ewing Tests for cardiac autonomic neuropathy: Beat-to-Beat heart rate variation, Heart rate response to standing, Heart rate response to valsalva maneuver, Systolic blood pressure response to standing. All tests have been performed with the same physician and aid
at recruitment
Primary Number of Patients With Bladder Autonomic Neuropathy History of recurrent urine tract infection and/or dysuria and/or incomplete bladder emptying
Post voiding residual(PVR) measurement with abdominal echography by a radiologist
Cystomanometry is performed if PVR > 50 ml
In men the prostatic measurement was made in all patients. In women, we measured the volume of uterus.
at recruitment
Primary Number of Patients With Gastro-intestinal Autonomic Neuropathy We interviewed all patient, looking for a history of post prandial discomfort or bad gastric emptying sensation or vomiting or unexplained diarrhea or constipation
We performed an endoscopic examination to exclude other causes in patients with a positive history of gastro-intestinal troubles.
at recruitment
Primary Number of Patients With Erectile Dysfunction - Questionary: onset , drug use, medical history, psycho- social conditions at recruitment
Secondary Number of Patients With New Cardiac Events During Follow-up We Record every documented acute coronary syndrome during follow-up;
Each patient had an electrocardiogram every 3 months and during acute cardiovascular events;
Echocardiography has been performed if indicated by the cardiologist.
One year after recruitment
Secondary Number of Patients With New Stroke or Transient Ischemic Attack We assessed every new clinical signs of stroke with an interview searching for acute neurological symptoms and a clinical examination for all patients, from day one of recruitment to one year of follow-up;
Tomodensitometry if there was a clinical presentation of stroke. Magnetic resonance imaging if transient ischemic attack was suspected.
One year after recruitment
Secondary Number of Patients With Lower Limbs Atherothrombotic Accident During one year of follow-up :
We search for a recent history of intermittent claudication;
We perform a systematic clinical examination with palpation of lower limb pulses and an Ankle-Brachial Index measurement after one year or in the presence of an acute ischemic lower limb episod ;
Lower limb duplex sonography in the presence of an abnormal clinical vascular examination;
Angiography in the presence of a lower limbs vascular event.
One year after recruitment
Secondary Number of Patients That Died From Cardio Vascular Cause - We recorded each death and its cause from a medical record after hospitalization in emergency units or phone contact with the patient's relatives to have some news. The record began with recruitment. One year after recruitment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A